Christopher C Porter
Overview
Explore the profile of Christopher C Porter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
1396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nakano Y, Kuiper R, Nichols K, Porter C, Lesmana H, Meade J, et al.
Clin Cancer Res
. 2024 Sep;
30(22):5009-5020.
PMID: 39264246
Genomic instability disorders are characterized by DNA or chromosomal instability, resulting in various clinical manifestations, including developmental anomalies, immunodeficiency, and increased risk of developing cancers beginning in childhood. Many of...
2.
MacFarland S, Becktell K, Schneider K, Kuiper R, Lesmana H, Meade J, et al.
Clin Cancer Res
. 2024 Aug;
30(20):4566-4571.
PMID: 39190470
Gastrointestinal (GI) polyposis and cancer in pediatric patients is frequently due to an underlying hereditary cancer risk syndrome requiring ongoing cancer screening. Identification of at-risk patients through family history, clinical...
3.
Maese L, Wlodarski M, Kim S, Bertuch A, Bougeard G, Chang V, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4286-4295.
PMID: 39078402
Children harboring certain germline gene variants have an increased risk of developing myelodysplastic syndrome (MDS) and other hematopoietic malignancies (HM), such as leukemias and lymphomas. Recent studies have identified an...
4.
Das A, MacFarland S, Meade J, Hansford J, Schneider K, Kuiper R, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3378-3387.
PMID: 38860976
Replication repair deficiency (RRD) is a pan-cancer mechanism characterized by abnormalities in the DNA mismatch repair (MMR) system due to pathogenic variants in the PMS2, MSH6, MSH2, or MLH1 genes,...
5.
Ercan A, Aronson M, Fernandez N, Chang Y, Levine A, Liu Z, et al.
Lancet Oncol
. 2024 Mar;
25(5):668-682.
PMID: 38552658
Background: Constitutional mismatch repair deficiency (CMMRD) syndrome is a rare and aggressive cancer predisposition syndrome. Because a scarcity of data on this condition contributes to management challenges and poor outcomes,...
6.
The T-cell niche tunes immune function through modulation of the cytoskeleton and TCR-antigen forces
Kellner A, Hunter R, Do P, Eggert J, Jaffe M, Geitgey D, et al.
bioRxiv
. 2024 Feb;
PMID: 38352441
Obesity is a major public health crisis given its rampant growth and association with an increased risk for cancer. Interestingly, patients with obesity tend to have an increased tumor burden...
7.
Williams L, Williams K, Gillis N, Bolton K, Damm F, Deuitch N, et al.
Transplant Cell Ther
. 2023 Nov;
30(3):255-267.
PMID: 37913908
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a key treatment option for hematologic malignancies (HMs), although it carries significant risks. Up to 30% of patients relapse after allo-HSCT, of which...
8.
Mumme H, Raikar S, Bhasin S, Thomas B, Lawrence T, Weinzierl E, et al.
Genome Med
. 2023 Oct;
15(1):83.
PMID: 37845689
Background: Mixed phenotype acute leukemia (MPAL), a rare subgroup of leukemia characterized by blast cells with myeloid and lymphoid lineage features, is difficult to diagnose and treat. A better characterization...
9.
Mumme H, Thomas B, Bhasin S, Krishnan U, Dwivedi B, Perumalla P, et al.
Nat Commun
. 2023 Oct;
14(1):6209.
PMID: 37798266
Acute myeloid leukemia (AML) microenvironment exhibits cellular and molecular differences among various subtypes. Here, we utilize single-cell RNA sequencing (scRNA-seq) to analyze pediatric AML bone marrow (BM) samples from diagnosis...
10.
Pillsbury C, Dougan J, Rabe J, Fonseca J, Zhou C, Evans A, et al.
Cancer Res Commun
. 2023 Jul;
3(7):1248-1259.
PMID: 37465593
Significance: We demonstrate that Sig15 is overexpressed in hematologic malignancies driven by NFκB, is required for immune evasion in a mouse model of leukemia, and, for the first time, that...